Adagio Therapeutics

General Information

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. We are developing our lead product candidate, ADG20, for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants. COVID-19 has caused the current global pandemic that remains a significant global health crisis and has resulted in millions of deaths and lasting health problems in many survivors. We believe that COVID-19 will become an endemic disease requiring a variety of effective, safe and convenient treatment and prevention options for years to come. We aim to address COVID-19 and future potential viral outbreaks by building a portfolio of antibodies with broadly neutralizing activity against multiple members of the coronavirus family or additional viruses with pandemic potential. Our portfolio of antibodies was discovered by Adimab, LLC, or Adimab, an industry leader in translating target hypotheses into therapeutically relevant antibodies with their proprietary platform, which has resulted in more than 385 antibody discovery programs, over 40 of which have advanced into clinical trials.

(Note: Adagio Therapeutics upsized its IPO at pricing on Aug. 5, 2021, by pricing 18.2 million shares, up from 17.7 million shares in the prospectus, at $17 – the mid-point of its $16-to-$18 range – to raise $309.4 million.)

Employees: 68
Founded: 2020
Contact Information
Address 303 Wyman Street, Suite 300 Waltham, MA 02451, US
Phone Number (603) 252-2274
Web Address
View Prospectus: Adagio Therapeutics
Financial Information
Market Cap $1836.3mil
Revenues $0 mil (last 12 months)
Net Income $-104.0 mil (last 12 months)
IPO Profile
Symbol ADGI
Exchange NASDAQ
Shares (millions): 18.2
Price range $17.00 - $17.00
Est. $ Volume $309.4 mil
Manager / Joint Managers Morgan Stanley/ Jefferies/ Stifel/ Guggenheim Securities/
CO-Managers -
Expected To Trade: 8/6/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change